PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
5,000 participants
Sep 1, 2019
OBSERVATIONAL
Conditions
Summary
The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for comparative purpose a cohort of subjects with diabetes and/or obesity and/or other risk factors (i.e. psoriasis, IBD (inflammatory bowel disease), dyslipidemia) without NAFLD in order to have a clinical phenotypical characterization and the collection of biological specimens. We will collect clinical data, biological samples and imaging results in order to perform future cross-sectional studies and/or longitudinal studies for elucidating pathways of the disease and develop and validate biomarkers for diagnosis, prognosis and monitoring liver disease and comorbidities in order to contribute to precision medicine in this field.
Eligibility
Inclusion Criteria7
- Age ≥18 years
- Clinical phenotype of NAFLD (simple steatosis, NASH, metabolic cirrhosis, NAFLD-HCC) based on any of:
- Liver biopsy providing histological evidence of NAFLD or,
- Biochemical and/or radiological findings consistent with NAFLD
- Average alcohol consumption ≤21/14 units/week (males/females) in preceding 6 months and no history of sustained excessive consumption of alcohol in past 5 years.
- Clearance of HCV infection with new DAAs drugs with a SVR (sustained virological response) period \> 6 months
- Presence of risk factors for NAFLD (i.e. diabetes, metabolic syndrome, obesity, psoriasis) and absence of fatty liver at US
Exclusion Criteria3
- Refusal or inability (lack of capacity) to give informed consent.
- Average alcohol ingestion \>21/14 units/week (males/females) in preceding 6 months or history of sustained excessive consumption of alcohol in past 5 years.
- History or presence of Type 1 diabetes mellitus.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04371042